Investor Conference Participation by Design Therapeutics
Design Therapeutics, Inc. (NASDAQ: DSGN), a pioneering biotechnology company based in Carlsbad, California, is preparing to take part in significant investor conferences. These events provide a platform for discussing their groundbreaking work in developing treatments aimed at serious degenerative genetic diseases.
Conference Schedule
The management team of Design Therapeutics will engage in fireside chats at two prominent healthcare conferences:
Piper Sandler 37th Annual Healthcare Conference
This event is scheduled for a Wednesday in December, where Design Therapeutics will present at 3:30 p.m. ET in New York. It is an excellent opportunity to connect with investors and share insights into their innovative therapies.
Evercore 8th Annual Healthcare Conference
The following day, the company will make another appearance at the Evercore Healthcare Conference at 10:00 a.m. ET in Coral Gables, FL. This conference also aims to broaden their reach to potential investors interested in biotechnology.
Accessing Live Webcasts
Both fireside chats will be available through live webcasts. These sessions will be accessible via the investor section of the Design Therapeutics website, enabling both current shareholders and interested investors to engage with the presentations. The archived webcasts will remain accessible for at least 30 days, ensuring a broader audience can still catch the discussions and insights shared during these conferences.
Innovative Approaches in Biotechnology
Design Therapeutics is dedicated to advancing a new class of therapies through its proprietary GeneTAC® platform. This innovative approach allows manipulation of gene expression with high precision, focusing on treating the root causes of genetic diseases. Programs currently in the pipeline include DT-216P2 for Friedreich ataxia and DT-168 for Fuchs endothelial corneal dystrophy. The company is also advancing DT-818 for myotonic dystrophy type-1 and is exploring avenues to address Huntington's disease.
About Design Therapeutics
As a clinical-stage biotechnology company, Design Therapeutics is on a mission to revolutionize treatment options for severe genetic disorders. By leveraging their GeneTAC® technologies, they aim to rectify dysfunctional genes, harnessing the body’s inherent mechanisms to restore health. The company is also dedicated to ongoing discovery efforts for multiple genomic medicines, ensuring they remain at the forefront of innovative therapeutic development.
Contact Information
For further inquiries, please reach out to:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
Frequently Asked Questions
What is the focus of Design Therapeutics?
Design Therapeutics focuses on developing therapies for serious degenerative genetic diseases using its GeneTAC® platform.
When will Design Therapeutics present at the conferences?
Design Therapeutics will participate in two conferences: Piper Sandler on December 3 and Evercore Healthcare on December 4.
How can investors access the presentations?
Investors can access live webcasts of the presentations through the Design Therapeutics website.
What therapies are currently in development?
Current therapies in development include DT-216P2, DT-168, and DT-818 for various genetic diseases.
Who can be contacted for more information?
Inquiries can be directed to Renee Leck at THRUST Strategic Communications via email.